Topics:
Thoracic Malignancies • Medical Oncology
How do you handle Grade 3-4 standard infusion reactions with Amivantamab?
Does reducing the rate of infusion, or adding Montelukast reduce chances of future reactions?
Answer from: Medical Oncologist at Academic Institution
Fortunately, G3+ infusion reactions with amivantamab are uncommon. In the CHYSALIS phase I study which led to approval for EGFR exon 20 (Park et al., PMID 34339292), G3+ infusion reactions were only seen in 3% of patients. But grade 1-2 infusion reactions were fairly common.Infusion reactions tend t...
Sign in or Register to read more